Careers
Developer of novel cancer treatments designed to target DNA damage response. The company's treatments focus on developing therapies through Deoxyribonucleic Acid damage response pathways to help mutations to their DNA so that they can evolve, enabling physicians to selectively kill cancer cells through a concept known as synthetic lethality. We have built an extensive DDR focused pipeline designed to address areas of high unmet needs across solid tumour indications including our ATR inhibitor, ART0380, and our Polθ inhibitor ART6043, as monotherapy and combination treatments. Together with our research collaborations with premiere institutions like Cancer Research UK, The Institute of Cancer Research, The Netherlands Cancer Institute, and the Crick Institute we are pioneering validated approaches to DDR drug discovery.